Long-term Cardiovascular, Renal, and Safety Outcomes of Teprotumumab versus Systemic Glucocorticoids in Thyroid Eye Disease

doi:10.1016/j.ophtha.2025.05.012

Long-term Cardiovascular, Renal, and Safety Outcomes of Teprotumumab versus Systemic Glucocorticoids in Thyroid Eye Disease

2025-05-19

0

PRE

AI

DOI：10.1016/j.ophtha.2025.05.012

Original

Original request for help

Save

Abstract

En 中文

The insulin-like growth factor-1 receptor inhibitor teprotumumab is effective for thyroid eye disease (TED), but there is limited evidence on its long-term safety. We studied the long-term cardiovascular, renal, infectious, and safety outcomes of teprotumumab compared with intravenous (IV) glucocorticoids (GCs), oral GCs, and conservative treatment in patients with TED.

Long-term Cardiovascular, Renal, and Safety Outcomes of Teprotumumab versus Systemic Glucocorticoids in Thyroid Eye Disease

Abstract

Journal

Organization